Please login to the form below

Not currently logged in
Email:
Password:

Afinitor

This page shows the latest Afinitor news and features for those working in and with pharma, biotech and healthcare.

AAA board presses go on $3.9bn Novartis takeover

AAA board presses go on $3.9bn Novartis takeover

Novartis has no heritage in this type of medicine but already markets two drugs for NET – Sandostatin (octreotide) and Afinitor/Votubia (everolimus) – so the acquisition makes sense from a franchise perspective, ... Latterly Sandostatin has played

Latest news

  • NICE gives green light to Ipsen's Cabometyx NICE gives green light to Ipsen's Cabometyx

    Earlier this year NICE performed a similar U-turn on Novartis’ kidney cancer drug Afinitor, following an offer of discount earlier and the provision of new evidence.

  • NICE U-turn on Novartis' Afinitor for kidney cancer NICE U-turn on Novartis' Afinitor for kidney cancer

    The UK's National Institute for Health and Care Excellence (NICE) has reversed its previous ruling on Afinitor and is set to recommend the drug for routine NHS use in kidney ... cancer. The U-turn on NICE's 2011 decision comes as the regulator continues

  • NICE backs Novartis' Afinitor and Pfizer's Xalkori NICE backs Novartis' Afinitor and Pfizer's Xalkori

    NICE has provisionally recommended Novartis' Afinitor and Pfizer's Xalkori for routine use on the NHS in breast and non-small cell lung cancer (NSCLC) in draft guidance published today. ... Afinitor (everolimus) has been backed as a combination treatment

  • NICE U-turn on Opdivo for kidney cancer NICE U-turn on Opdivo for kidney cancer

    In a phase III clinical study, patients treated with Opdivo lived for an average of 5.4 months longer than the group who received Novartis' Afinitor (everolimus), the standard therapy, and

  • The UK's new Cancer Drugs Fund The UK's new Cancer Drugs Fund

    Since then NICE's deliberations over how to apply the new rules have caused considerable uncertainty for Novartis' breast cancer therapy Afinitor (everolimus) and Janssen's Imbruvica (ibrutinib) for mantle cell

More from news
Approximately 12 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    The successes of Gilenya, Afinitor/Votubia, Galvus, Tasigna and Jakavi - as well as its generics arm, Sandoz - mean that Novartis is now less than $500m behind Pfizer in second place.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer);

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    In 2010, we had 13 key product approvals and 16 major filings in pharma, including Gilenya, Lucentis and Afinitor," he points out. ... populations. "In Q2 alone, we had four major approvals and two major filings, including Afinitor, Arcapta Neohaler,

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    patients the comparator was a different targeted therapy, Afinitor (everolimus), rather than Nexavar - although for cytokine-pretreated patients the trial comparator could be used.The G-BA still exercises its right

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Study Report

Market Study Report is a hub for market intelligence products and services. We streamline the purchase of your market research...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics